Holden Lowell Thomas's Form 4 filing
Nascent Biotech Inc. (NBIO) · filed Feb 2, 2023
- Accession no.
- 0001477932-23-000693
- Filed
- Feb 2, 2023, 3:04 PM ET
- Trade date
- Jan 27, 2023
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $2.80K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Holden Lowell ThomasCIK 0001479734 | Director, Officer (CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2023 | Common Stock | PPurchaseAcquired | +20,000 | $0.14 | +$2,800 | 8,418,277 | Direct | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.